Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether sitagliptin is effective in preventing the
development of new-onset diabetes after kidney transplant (NODAT). Up to one-third of
previously non-diabetic patients develop NODAT after a kidney transplant. Corticosteroids and
calcineurin inhibitors are two commonly utilized anti-rejection medications that contribute
to diabetes development through multiple mechanisms; including decreased insulin production
by the pancreas. Sitagliptin is an oral medication that results in increased insulin
secretion. We hypothesize that administration of sitagliptin to transplant recipients
identified to be at risk for diabetes development will reduce the incidence and severity of
NODAT.